JPY 84.0
(-3.45%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 26 Million JPY | -51.25% |
2022 | 59.48 Million JPY | 612.36% |
2021 | 8.35 Million JPY | -92.74% |
2020 | 115.09 Million JPY | -32.24% |
2019 | 169.86 Million JPY | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 231.47 Million JPY | 0.0% |
2024 Q1 | - JPY | -100.0% |
2023 Q4 | 250 Thousand JPY | -98.88% |
2023 FY | 29 Million JPY | -51.25% |
2023 Q3 | 22.32 Million JPY | 0.0% |
2023 Q2 | - JPY | -100.0% |
2023 Q1 | 6.96 Million JPY | -86.07% |
2022 Q4 | 50 Million JPY | 0.0% |
2022 FY | 59.48 Million JPY | 612.36% |
2022 Q3 | - JPY | 0.0% |
2021 FY | 8.35 Million JPY | -92.74% |
2020 FY | 115.09 Million JPY | -32.24% |
2019 FY | 169.86 Million JPY | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Pharma Foods International Co., Ltd. | 62.14 Billion JPY | 99.958% |
Takeda Pharmaceutical Company Limited | 4263.76 Billion JPY | 99.999% |
Sumitomo Pharma Co., Ltd. | 314.55 Billion JPY | 99.992% |
Shionogi & Co., Ltd. | 435.08 Billion JPY | 99.994% |
Wakamoto Pharmaceutical Co.,Ltd. | 7.73 Billion JPY | 99.664% |
Nippon Shinyaku Co., Ltd. | 148.25 Billion JPY | 99.982% |
Kaken Pharmaceutical Co., Ltd. | 72.04 Billion JPY | 99.964% |
Eisai Co., Ltd. | 741.75 Billion JPY | 99.996% |
Morishita Jintan Co., Ltd. | 12.4 Billion JPY | 99.79% |
Hisamitsu Pharmaceutical Co., Inc. | 141.7 Billion JPY | 99.982% |
Mochida Pharmaceutical Co., Ltd. | 102.88 Billion JPY | 99.975% |
Fuso Pharmaceutical Industries,Ltd. | 55.4 Billion JPY | 99.953% |
Nippon Chemiphar Co., Ltd. | 30.74 Billion JPY | 99.915% |
Tsumura & Co. | 150.84 Billion JPY | 99.983% |
Kissei Pharmaceutical Co., Ltd. | 75.57 Billion JPY | 99.966% |
Torii Pharmaceutical Co., Ltd. | 54.63 Billion JPY | 99.952% |
Towa Pharmaceutical Co., Ltd. | 227.93 Billion JPY | 99.989% |
Fuji Pharma Co., Ltd. | 40.88 Billion JPY | 99.936% |
Zeria Pharmaceutical Co., Ltd. | 75.72 Billion JPY | 99.966% |
KYORIN Holdings, Inc. | 119.53 Billion JPY | 99.978% |
Taiko Pharmaceutical Co.,Ltd. | 5.04 Billion JPY | 99.484% |
Daito Pharmaceutical Co.,Ltd. | 46.89 Billion JPY | 99.945% |
SymBio Pharmaceuticals Limited | 5.58 Billion JPY | 99.535% |
Mizuho Medy Co.,Ltd. | 10.98 Billion JPY | 99.763% |
Solasia Pharma K.K. | 617 Million JPY | 95.786% |
Modalis Therapeutics Corporation | - JPY | -Infinity% |
ASKA Pharmaceutical Holdings Co.,Ltd. | 62.84 Billion JPY | 99.959% |
Sawai Group Holdings Co., Ltd. | 176.86 Billion JPY | 99.985% |
Cyfuse Biomedical K.K. | 61.11 Million JPY | 57.455% |
Toho Holdings Co., Ltd. | 1476.71 Billion JPY | 99.998% |
Koa Shoji Holdings Co.,Ltd. | 22.13 Billion JPY | 99.883% |